Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy
- 1 November 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (9) , 2714-2721
- https://doi.org/10.1182/blood-2004-02-0627
Abstract
Hemophilia B, also known as Christmas disease, arises from mutations in the factor IX ( F9 ) gene. Its treatment in humans, by recombinant protein substitution, is expensive, thus limiting its application to intermittent treatment in bleeding episodes and prophylaxis during surgery; development of inhibitory antibodies is an associated hazard. This study demonstrates permanent therapeutic correction of his disease without development of immune reactions by introduction of an HIV-based lentiviral vector encoding the human factor IX protein into the fetal circulation of immunocompetent hemophiliac and normal outbred mice. Plasma factor IX antigen remained at around 9%, 13%, and 16% of normal in the 3 hemophilia B mice, respectively, until the last measurement at 14 months. Substantial improvement in blood coagulability as measured by coagulation assay was seen in all 3 mice and they rapidly stopped bleeding after venipuncture. No humoral or cellular immunity against the protein, elevation of serum liver enzymes, or vector spread to the germline or maternal circulation were detected. (Blood. 2004;104: 2714-2721)Keywords
This publication has 31 references indexed in Scilit:
- Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent miceGene Therapy, 2003
- On the scientific and ethical issues of fetal somatic gene therapyGene Therapy, 2002
- High-Level Transduction and Gene Expression in Hematopoietic Repopulating Cells Using a Human Imunodeficiency Virus Type 1-Based Lentiviral Vector Containing an Internal Spleen Focus Forming Virus PromoterHuman Gene Therapy, 2002
- Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vectorNature Biotechnology, 2002
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in LiverMolecular Therapy, 2000
- Persistent expression of canine factor IX in hemophilia B caninesGene Therapy, 1999
- Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectorsGene Therapy, 1998
- Retroviral gene transfer to the liver in vivo during tri-iodothyronine induced hyperplasiaGene Therapy, 1998
- Multiply attenuated lentiviral vector achieves efficient gene delivery in vivoNature Biotechnology, 1997